Brutonâ€s Tyrosine Kinase (BTK) Inhibitors in Clinical T

Current Hematologic Malignancy Reports
9, 44-49
DOI: 10.1007/s11899-013-0188-8

Citation Report

#	Article	IF	Citations
1	Genetic Abnormalities in Chronic Lymphocytic Leukemia: Where We Are and Where We Go. BioMed Research International, 2014, 2014, 1-13.	0.9	106
2	The Non-receptor Tyrosine Kinase Tec Controls Assembly and Activity of the Noncanonical Caspase-8 Inflammasome. PLoS Pathogens, 2014, 10, e1004525.	2.1	40
3	Diseaseâ€specific mutations in mature lymphoid neoplasms: Recent advances. Cancer Science, 2014, 105, 623-629.	1.7	14
4	Ibrutinib:â€ From Molecule to Medicine. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2014, 24, 4-14.	0.1	0
5	Brutonâ€™s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Therapeutic Advances in Hematology, 2014, 5, 121-133.	1.1	57
6	Overcoming bortezomib resistance in multiple myeloma. Biochemical Society Transactions, 2014, 42, 804-808.	1.6	51
7	Mantle cell lymphoma: evolving management strategies. Blood, 2015, 125, 48-55.	0.6	155
8	Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. Journal of Hematology and Oncology, 2015, 8, 85.	6.9	29
9	Bruton’s tyrosine kinase in chronic inflammation: from pathophysiology to therapy. International Journal of Interferon, Cytokine and Mediator Research, 2015, , 27.	1.1	1
10	A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Therapeutics and Clinical Risk Management, 2015, 11, 979.	0.9	24
11	Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discovery Today, 2015, 20, 1061-1073.	3.2	400
12	Phenotypic Approaches to Identify Inhibitors of B Cell Activation. Journal of Biomolecular Screening, 2015, 20, 876-886.	2.6	3
13	Ibrutinib for the treatment of WaldenstrÃ¶m macroglobulinemia. Expert Review of Hematology, 2015, 8, 569-579.	1.0	14
14	Brutonâ€™s tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 229-235.	1.4	23
15	Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia. Drugs, 2015, 75, 769-776.	4.9	35
16	Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Annals of Hematology, 2015, 94, 2025-2032.	0.8	26
17	Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1371-1391.	1.5	6
18	Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. Oncotarget, 2016, 7, 70623-70638.	0.8	21

#	Article	IF	Citations
19	Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents. Oncotarget, 2016, 7, 48692-48731.	0.8	51
20	Novel Pharmacotherapies for B-Cell Lymphomas and Leukemias. American Journal of Therapeutics, 2016, 23, e498-e520.	0.5	1
21	Stable isotopeâ€labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults. British Journal of Clinical Pharmacology, 2016, 81, 235-245.	1.1	56
22	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood, 2016, 128, 574-583.	0.6	69
23	B cell receptor inhibition as a target for CLL therapy. Best Practice and Research in Clinical Haematology, 2016, 29, 2-14.	0.7	9
24	Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2 (BMS-986142): A Reversible Inhibitor of Brutonâ€™s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers. Journal of Medicinal Chemistry, 2016, 59, 9173-9200.	2.9	111
25	Small Molecule Reversible Inhibitors of Brutonâ€™s Tyrosine Kinase (BTK): Structureâ€“Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177). Journal of Medicinal Chemistry, 2016, 59, 7915-7935.	2.9	41
26	Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leukemia and Lymphoma, 2016, 57, 1517-1526.	0.6	4
27	Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. Molecular Cancer Therapeutics, 2016, 15, 2198-2208.	1.9	43
28	Mechanisms of NF-ÎºB deregulation in lymphoid malignancies. Seminars in Cancer Biology, 2016, 39, 3-14.	4.3	24
29	A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation. Oncogene, 2016, 35, 4368-4378.	2.6	53
30	Ibrutinib for mantle cell lymphoma. Future Oncology, 2016, 12, 477-491.	1.1	8
31	Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?. Expert Review of Hematology, 2016, 9, 245-254.	1.0	2
32	Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology, 2016, 97, 291-302.	2.0	12
33	The role of Brutonâ€™s tyrosine kinase in autoimmunity and implications for therapy. Expert Review of Clinical Immunology, 2016, 12, 763-773.	1.3	103
34	Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Brutonâ€™s tyrosine kinase for treatment of Rheumatoid arthritis. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1954-1957.	1.0	12
35	Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets. Leukemia and Lymphoma, 2016, 57, 134-142.	0.6	3
36	Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. Leukemia, 2017, 31, 177-185.	3.3	40

#	Article	IF	Citations
37	Design and Synthesis of Novel Pyrazolo[3,4â€d]pyrimidinâ€1â€yl piperidine Derivatives as Bruton's Tyrosine Kinase Inhibitors. Bulletin of the Korean Chemical Society, 2017, 38, 278-281.	1.0	5
38	Novel agents in mantle cell lymphoma. Expert Review of Anticancer Therapy, 2017, 17, 491-506.	1.1	7
39	Discovery of new BTK inhibitors with B cell suppression activity bearing a 4,6-substituted thieno[3,2-d]pyrimidine scaffold. RSC Advances, 2017, 7, 26060-26069.	1.7	8
40	The Transcriptional Landscape of p53 Signalling Pathway. EBioMedicine, 2017, 20, 109-119.	2.7	47
41	Population Pharmacokinetics and Exposure Response Assessment of CCâ€292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Pharmacology, 2017, 57, 1279-1289.	1.0	11
42	Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics. Molecular Cancer Therapeutics, 2017, 16, 1054-1067.	1.9	40
43	Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood, 2017, 129, 1155-1165.	0.6	64
44	Reply. Arthritis and Rheumatology, 2017, 69, 475-477.	2.9	0
45	Evolution of Small-Molecule Immunology Researchâ€"Changes Since CMC II. , 2017, , 395-419.		0
46	Kinase inhibitors: the road ahead. Nature Reviews Drug Discovery, 2018, 17, 353-377.	21.5	679
47	The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. European Journal of Medicinal Chemistry, 2018, 151, 315-326.	2.6	129
48	Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors. MedChemComm, 2018, 9, 697-704.	3.5	5
49	Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors. Drug Discovery Today, 2018, 23, 76-89.	3.2	39
50	Companion animals in comparative oncology: One Medicine in action. Veterinary Journal, 2018, 240, 6-13.	0.6	50
51	Emerging Biomarkers and Therapeutic Pipelines for Chronic Spontaneous Urticaria. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1108-1117.	2.0	47
52	Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7285-E7292.	3.3	265
53	Challenges and Opportunities for Childhood Cancer Drug Development. Pharmacological Reviews, 2019, 71, 671-697.	7.1	13
54	Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Brutonâ€™s tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 3390-3395.	1.4	5

#	Article	IF	Citations
55	Optimization of novel reversible Brutonâ€™s tyrosine kinase inhibitors identified using Tethering-fragment-based screens. Bioorganic and Medicinal Chemistry, 2019, 27, 2905-2913.	1.4	14
56	Structural mechanism for Brutonâ€™s tyrosine kinase activation at the cell membrane. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9390-9399.	3.3	49
57	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis. European Journal of Medicinal Chemistry, 2019, 169, 121-143.	2.6	21
58	Covalent binders in drug discovery. Progress in Medicinal Chemistry, 2019, 58, 1-62.	4.1	32
59	Emerging roles of and therapeutic strategies targeting BRD4 in cancer. Cellular Immunology, 2019, 337, 48-53.	1.4	86
60	Bruton's Tyrosine Kinase (BTK) Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 109-124.		2
61	Fluorescence anisotropy imaging in drug discovery. Advanced Drug Delivery Reviews, 2019, 151-152, 262-288.	6.6	51
62	New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia. Bioorganic Chemistry, 2020, 94, 103361.	2.0	13
63	Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRNâ€473) in the treatment of canine pemphigus foliaceus. Veterinary Dermatology, 2020, 31, 291.	0.4	15
64	Modeling the Antileukemia Activity of Ellipticine-Related Compounds: QSAR and Molecular Docking Study. Molecules, 2020, 25, 24.	1.7	19
65	Realâ€world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. European Journal of Haematology, 2020, 105, 646-654.	1.1	34
66	The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. Frontiers in Immunology, 2020, 11, 1991.	2.2	124
67	HZ-A-005, a potent, selective, and covalent Brutonâ€™s tyrosine kinase inhibitor in preclinical development. Bioorganic Chemistry, 2020, 105, 104377.	2.0	4
68	Novel Therapies for Pemphigus Vulgaris. American Journal of Clinical Dermatology, 2020, 21, 765-782.	3.3	9
69	Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMSâ€986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placeboâ€controlled trial in healthy participants. British Journal of Clinical Pharmacology, 2020, 86, 1849-1859.	1.1	17
70	Transition metal complexes of 6â€mercaptopurine: Characterization, Theoretical calculation, DNAâ€Binding, molecular docking, and anticancer activity. Applied Organometallic Chemistry, 2021, 35, e6041.	1.7	33
71	Brutonâ€™s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 2439-2451.	2.0	19
72	Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy, 2021, 6, 201.	7.1	607

#	Article	IF	Citations
73	Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. International Journal of Molecular Sciences, 2021, 22, 7641.	1.8	30
74	Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases. Molecules, 2021, 26, 4907.	1.7	31
75	The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015â€“2020. Bioorganic Chemistry, 2021, 113, 105011.	2.0	22
76	An update of new small-molecule anticancer drugs approved from 2015 to 2020. European Journal of Medicinal Chemistry, 2021, 220, 113473.	2.6	27
77	Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. Oncotarget, 2017, 8, 7201-7207.	0.8	27
78	Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder. Oncotarget, 2015, 6, 18250-18264.	0.8	53
80	The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. Journal of Experimental Pharmacology, 2021, Volume 13, 923-935.	1.5	11
81	Chronic Spontaneous Urticaria: A Review of Pathological Mechanisms, Diagnosis, Clinical Management, and Treatment. European Medical Journal (Chelmsford, England), 0, , 29-39.	3.0	1
82	Research Progress of BTK Inhibitors in the Treatment of Inflammatory and Autoimmune Diseases. Hans Journal of Medicinal Chemistry, 2022, 10, 70-83.	0.0	1
83	Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases. European Journal of Medicinal Chemistry, 2022, 239, 114551.	2.6	11
84	BTK Inhibitors in Haematology: Beyond B Cell Malignancies. Transfusion Medicine Reviews, 2022, , .	0.9	0
85	Development of a UPLC-MS/MS method for the determination of orelabrutinib in rat plasma and its application in pharmacokinetics. Frontiers in Pharmacology, 0, 13, .	1.6	2
86	Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Brutonâ€™s Tyrosine Kinase via Molecular Dynamics Simulations. Molecules, 2022, 27, 7451.	1.7	1
87	BTK Isoforms p80 and p65 Are Expressed in Head and Neck Squamous Cell Carcinoma (HNSCC) and Involved in Tumor Progression. Cancers, 2023, 15, 310.	1.7	3